Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Multiple Myeloma 2Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Cisplatin 21Etoposide 20Carboplatin 20Topotecan 13pembrolizumab 12durvalumab 11Paclitaxel 10Irinotecan 9Nivolumab 7Gemcitabine 7tremelimumab 6atezolizumab 6Radiotherapy 6Docetaxel 6Pemetrexed 5Ipilimumab 5Cyclophosphamide 5rovalpituzumab tesirine 4budigalimab 4Specimen Handling 4Injections 4Doxorubicin 4Bortezomib 4130-nm albumin-bound paclitaxel 4venetoclax 3talazoparib 3olaparib 3fludarabine 3etoposide phosphate 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Small Cell Lung Carcinoma × lorvotuzumab mertansine × Clear all
NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ImmunoGen, Inc.

Phase 1 Completed
97 enrolled
DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡